TELA Bio Reports First Quarter 2025 Financial Results

About this update from Tela Bio, Inc.

[{"type":"image","alt":"TELA Bio, Inc.","displaySize":"","headline":null,"caption":"TELA Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":81,"url":"https://media.zenfs.com/en/globenewswire.com/8d626409a8c31e4dc7fea09f34dc0ef7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7TF7cdHGILp3Xeeqsee8gQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8d626409a8c31e4dc7fea09f34dc0ef7","width":300,"height":81}},"lazy":false},{"type":"text","content":"MALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2025.","length":278,"tagName":"p"},{"type":"text","content":"Recent Highlights","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Delivered revenue of $18.5 million in the first quarter 2025, representing growth of 12% over the prior year period and sequential growth of 5% over the fourth quarter of 2024;","length":176,"tagName":"p"}]},{"val":[{"type":"text","content":"Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the first quarter, resulting in year-over-year revenue increase for each product of approximately 15% and 2%, respectively;","length":208,"tagName":"p"}]},{"val":[{"type":"text","content":"Commenced full U.S. commercial launch of larger sized OviTex PRS for use in plastic and reconstructive surgery, which may reduce the need for multiple small pieces and have the potential to simplify more complex plastic and reconstructive procedures;","length":250,"tagName":"p"}]},{"val":[{"type":"text","content":"Reiterated full year 2025 revenue guidance of $85.0 million to $88.0 million, representing 23% to 27% year-over-year growth.","length":124,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":758,"olType":false},{"type":"text","content":"“We are pleased with the strong performance in the first quarter of 2025 following the realignment and optimization of our sales organization,” said Antony Koblish, President and CEO of TELA Bio. “The complementary dynamic between our Territory Managers and Account Specialists enabled new account wins and greater market penetration a...

More updates from Tela Bio, Inc.